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Introduction
Disorders of reproduction represent a significant social,
medical, and economic burden for individuals and society.
Approximately 1 in 10 couples in the United States are in-
fertile, and each partner is equally likely to be affected (1).
Although many causes of infertility can now be determined
in both men and women, most couples still receive a diag-
nosis of idiopathic infertility. A subset of these patients is
likely to have an underlying genetic disorder that is either
inherited (germline) or acquired (somatic). Although the
most severe genetic reproductive disorders cause dysgenetic
gonads or abnormal hormonal profiles, milder phenotypes
are being recognized with increasing frequency.
Over the past decade, many genes have been identified
that influence the development and function of the hypo-
thalamic-pituitary-gonadal (HPG) axis. These genes encode
an array of transcription factors, matrix proteins, hormones,
receptors, and enzymes that are expressed at multiple levels
of the HPG axis, and regulate the complex developmental,
paracrine, and endocrine interactions that are necessary for
spermatogenesis and ovulation.
Identifying naturally occurring genetic mutations pro-
vides unique insight into the role that these factors play in the
human HPG axis. In addition, defining the genetic basis of
disease has significant benefits for the patients, as appropri-
ate and educated counseling can be provided and treatment
tailored to the individual. In this review, we focus on single
gene mutations that affect the HPG axis in humans. Space
limitations preclude discussion of the many chromosomal
anomalies (e.g. XO, XXY), metabolic alterations (e.g. GALT),
steroidogenic defects (e.g. CYP21), or activating mutations
(e.g. Gs, LH-receptor) that also can disrupt human repro-
duction. Progress resulting from the human genome project,
along with advances in genomics and proteomics, will un-
doubtedly enhance the rate at which human reproductive
mutations are found. Capitalizing on these scientific ad-
vances to improve patient care will be a major opportunity
of the next decade.
GnRH release and action
Abnormalities in GnRH function can result from aberrant
neuronal migration, defective synthesis and release of
GnRH, or mutations in the GnRH receptor. The clinical re-
sponse to pulsatile GnRH therapy is often useful to discrim-
inate defects in hormone synthesis vs. action (Fig. 1 and
Table 1).
KAL and Kallmann syndrome (KS). During development,
GnRH-releasing neurons originate in the olfactory placode
and migrate with olfactory neurons through the cribiform
plate to the olfactory bulb and into the fetal hypothalamus.
Abnormalities in these migratory processes explain the as-
sociation of hypogonadotropic hypogonadism (HH) with
anosmia (absent sense of smell) in patients with KS (2).
Mutations or deletions in the gene KAL cause the X-linked
form of KS (2, 3). KAL encodes an extracellular matrix gly-
coprotein, anosmin-1, which facilitates neuronal growth and
migration. Most KAL mutations affect the putative fibronec-
tin repeat region of the anosmin-1 and interfere with the
migration of olfactory and GnRH neurons into the olfactory
bulb. The migrational arrest of GnRH neurons within the
meninges has been reported in a study of a 19-wk human
fetus with X-linked KS, and olfactory bulb agenesis or hy-
poplasia has been detected by MRI in some patients with this
condition.
Most patients with X-linked KS have a micropenis and
bilaterally undescended testes at birth, reflecting congenital
GnRH and gonadotropin insufficiency. HH becomes appar-
ent in adolescence as a failure of pubertal development.
Consistent with the hypothalamic defect, patients with X-
linked KS typically respond to pulsatile GnRH priming with
an increase in gonadotropin release over several days, and
pulsatile GnRH has been used successfully to induce fertility
in patients with KAL mutations (4). However, recombinant
gonadotropins are also effective and are easier for most phy-
sicians to administer.
KAL/anosmin-1 is also expressed in the developing Pur-
kinje cells of the cerebellum, meso-, and meta-nephros, oc-
Abbreviations: AHC, Adrenal hypoplasia congenita; AMH, anti-
Mullerian hormone; CPHD, combined pituitary hormone deficiency;
DAX1, dosage sensitive sex reversal-AHC critical region on the X chro-
mosome, gene 1; DHT, dihydrotestosterone; hCG, human CG; HESX1,
homeobox gene expressed in ES cells; HH, hypogonadotropic hypogo-
nadism; HPG, hypothalamic-pituitary-gonadal; KS, Kallmann syn-
drome; LHX3, Lim homeobox gene 3; PROP-1, Prophet of Pit-1; SF1,
steroidogenic factor-1; SOX, SRY-related HMG-box gene; Sry, sex-
determining region Y.
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ulomotor nucleus, and facial mesenchyme, explaining the
association of X-linked KS with synkinesia (mirror image
movements), renal agenesis, visual abnormalities and mid-
line facial defects (5). Unilateral renal agenesis is common,
and may be present in family members in the absence of
anosmia or HH. This variable penetrance of features is com-
mon in families with KAL mutations, suggesting that mod-
ifier genes or epigenetic phenomena influence phenotypic
expression (4). Furthermore, the association of anosmia with
HH due to an apparently autosomal dominant or recessive
mode of inheritance in some families indicates that addi-
tional genes are involved in GnRH neuronal migration (6).
Obesity, metabolism, and reproduction. Although associations
between obesity, metabolism, and reproduction have been
proposed for many years, these complex interactions are now
beginning to be unraveled. For example, direct evidence for
the role of leptin in reproductive function is provided by the
HH seen in patients with obesity due to mutations in leptin
(7) or the leptin receptor (8), as well as the ob/ob mouse. It
appears likely that leptin facilitates HPG activity through its
central action on GnRH release. Recombinant leptin therapy
has been used successfully to induce pulsatile gonadotropin
activity and puberty, as well as weight loss, in a girl with
congenital leptin deficiency (9). Preliminary data suggest
that leptin treatment does not induce premature puberty in
younger children. Therefore, leptin appears to be necessary
but not sufficient for pubertal development.
Mutations in the endopeptidase, prohormone conver-
tase-1, have been described in association with obesity, HH
and hypocortisolemia (10). Prohormone convertase-1 regu-
lates posttranslational modification of prohormones and
neuropeptides, but it is unclear whether the reproductive
defects reported result from impaired GnRH processing, ab-
normalities in neuropeptides related to GnRH secretion, or
an alternative mechanism.
Recently, hypothalamic-gonadotrope dysfunction has
been reported in female mice with targeted deletion of in-
sulin-related substrate-2, -4, or tissue-specific (neuronal) de-
letion of the insulin receptor. Although HH has not been
reported in patients with insulin receptor mutations, these
signaling systems are likely to play an important role in
human reproductive function. The relationship of insulin
resistance, increased LH secretion, and hyperandrogenemia
in polycystic ovary syndrome remain enigmatic but also
suggests an interplay between insulin action and reproduc-
tion. It is notable that patients with monogenic obesity due
to mutations in POMC or the melanocortin-4 receptor do not
have reproductive abnormalities, suggesting that the mela-
nocortin system regulates appetite and body weight without
influencing the HPG axis.
GnRH and the GnRH receptor. No human GnRH mutations
have been reported, although some rare cases of hypogo-
nadism have been described in patients with 8p deletions
and the hpg/hpg mouse is hypogonadal due to a GnRH gene
deletion.
An increasing number of GnRH receptor mutations have
been described. It currently appears that up to 20% of pa-
tients with idiopathic HH may have mutations in this re-
ceptor (11–13). Most of these GnRH receptor mutations are
compound heterozygous changes that reduce GnRH binding
and/or activation of IP3 or PLC signaling pathways. At
present, R262Q mutations within the third intracellular loop
and Q106R mutations in the first extracellular loop of the
GnRH receptor occur most commonly.
The clinical features of patients with GNRHR mutations
are highly variable, even within the same kindred. At the
most severe end of the spectrum, complete loss of function
FIG. 1. Overview of the hypothalamic-pituitary (gonadotrope) axis.
Mutations in the genes listed in italics have been shown to cause HH
in humans.
TABLE 1. Single gene disorders in the HPG axis resulting in HH or abnormal gonadotropin release in humans
Gene Locus Inheritance Associated features
KAL Xp22 X-linked Anosmia, renal agenesis, synkinesia, cleft lip/palate,
oculomotor/visuospatial defects, gut malrotations
Leptin/R 7q31/1p31 AR Obesity
PC1 5q15–21 AR Obesity, hypocortisolemia
GNRHR 4q21 AR
HESX1 3p21 AR Septo-optic dysplasia, CPHD
AD Isolated GH insufficiency
LHX3 9q34 AR CPHD (ACTH spared), cervical spine rigidity
PROP1 5q35 AR CPHD (ACTH usually spared)
FSH 11p13 AR 1 LH
LH 19q13 AR 1 LH (bioinactive), (1 FSH)
SFI (NR5A1) 9p33 AD/AR Primary adrenal failure, XY sex reversal, uterus
DAX1 (NROB1) Xp21 X-linked Primary adrenal failure, impaired spermatogenesis
AD, Autosomal dominant; AR, autosomal recessive. Other features may be seen in patients with contiguous gene deletion syndromes of Xp21
and Xp22 (e.g. Xp21: DAX1, glycerol kinase deficiency and Duchenne muscular dystrophy; Xp22: KAL, chondrodysplasia punctata and X-linked
ichthyosis).
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mutations (e.g. A129D, S168R) cause microphallus and cryp-
torchidism in males, complete failure of pubertal develop-
ment, and resistance to pulsatile GnRH treatment (14). In
contrast, milder loss of function mutations cause partial
GnRH resistance. Basal gonadotropins are detectable in these
patients and a modest gonadotropin response is seen after
bolus GnRH stimulation. Affected females can have spon-
taneous thelarche and normal breast development, and high-
dose pulsatile GnRH has been used to induce ovulation in
one woman with partial GnRH resistance (15). Affected
males may exhibit incomplete pubertal development. Larger
numbers of patients with impaired fertility and detectable
gonadotropins need to be evaluated to determine the true
prevalence of mild GnRH receptor mutations.
Anterior pituitary development
Mutations in several genes that regulate gonadotrope dif-
ferentiation and function have been described in patients
with combined pituitary hormone deficiency (CPHD) [e.g.
homeobox gene expressed in ES cells (HESX1), Lim ho-
meobox gene 3 (LHX3), Prophet of Pit-1 (PROP1)], but no
mutations in gonadotrope-specific genes have been de-
scribed yet (e.g. Egr1) (Fig. 1, Table 1).
HESX1. Targeted mutagenesis of the homeodomain tran-
scription factor Hesx1 in mice causes anterior central nervous
system defects and pituitary dysplasia, and a homozygous
R53C missense mutation in the DNA-binding region of
HESX1 has been reported in two children with septo-optic
dysplasia and CPHD (16). Although these children are pre-
pubertal, investigations show impaired gonadotropin re-
lease, and spontaneous pubertal development is unlikely.
Heterozygous mutations in other regions of HESX1 are as-
sociated with the milder phenotype of isolated GH insuffi-
ciency (17).
LHX3. Targeted mutagenesis of Lhx3/Lim3 causes panhypo-
pituitarism and early death in homozygous knockout mice.
Homozygous LHX3 mutations have been found in four pa-
tients from two families with features of CPHD (but pre-
served corticotrope function) and limited head rotation due
to cervical spine rigidity (18). One boy had cryptorchidism
and micropenis at birth, and the three oldest patients failed
to show signs of pubertal development by 15 yr of age and
there was evidence of impaired gonadotropin release. No-
tably, patients with mutations in the related transcription
factor LHX4 have CPHD with preserved reproductive
function.
PROP1. PROP1 was considered a candidate gene for pitu-
itary dysfunction following characterization of the Ames
dwarf (df) mouse (S83P), and mutations in this transcription
factor have now been reported in more than 50 families with
CPHD (19). Most patients with PROP1 mutations develop
GH and TSH deficiency in childhood. The onset of gonad-
otropin insufficiency is variable, even within families with
the same mutation; some patients demonstrate pubertal fail-
ure in adolescence whereas others develop hypogonadism or
secondary amenorrhea later in life (20). Although cortico-
trope function is usually preserved, progressive ACTH in-
sufficiency and hypocortisolemia have been reported in sev-
eral kindred.
Gonadotropins and gonadotropin receptors
The gonadotropins are heterodimers consisting of specific
-subunits that are noncovalently bound to a common -
subunit. No human-subunit mutations have been reported,
although disruption of all the glycoprotein hormones, in-
cluding TSH and human CG (hCG), would be expected.
Because hCG plays an essential role in the maintenance of
pregnancy in humans, a severe loss of function mutation in
the -subunit is unlikely to be found. A number of mutations
in the FSH and LH subunits and the gonadotropin recep-
tors have been reported (for review, see Ref. 21).
FSH and the FSH receptor. Mutations in FSH have been
reported in three women with delayed puberty, absent breast
development, and primary amenorrhea (22, 23). These ho-
mozygous or compound heterozygous mutations often affect
the seatbelt region of the protein, and interfere with the
synthesis and stability of the heterodimer complex. Conse-
quently, patients were found to have undetectable serum
FSH and elevated serum LH. Normal primordial follicles
were detected and, in two patients, exogenous FSH treatment
resulted in follicular maturation, ovulation, and fertility. This
ovarian phenotype suggests that FSH is not necessary for
primordial follicle development, but it is required for antral
development and granulosa cell estrogen production, as re-
ported following targeted disruption of FSH in female mice.
A block in folliculogenesis is also seen in female FSH
receptor knockout mice, and a similar but less severe phe-
notype results from homozygous mutations in the FSH re-
ceptor in humans (24). The highest prevalence of these mu-
tations is in Finland, where that A189V mutation is
associated with variable pubertal failure and primary or
secondary amenorrhea is reported. A milder clinical pheno-
type associated with a compound heterozygous mutation
has also been described, suggesting that subtler clinical phe-
notypes exist (25).
The role of FSH in spermatogenesis is less clear. Male
FSH and FSH receptor knockout mice are fertile despite
having reduced testicular volume and partial spermatogenic
failure, and men with FSH receptor mutations have variable
spermatogenic defects (26). In contrast, azoospermia has been
reported in two men with FSH gene mutations (27). Ad-
ditional cases of FSH and FSH receptor mutations are
needed, therefore, to clarify the role of FSH in spermatogen-
esis in humans.
LH and the LH receptor. Only one human LH gene mutation
has been reported to date in a man with delayed puberty, low
testosterone, and arrested spermatogenesis (28). This indi-
vidual presented with elevated serum immunoreactive LH
on presentation. However, a homozygous Q54R missense
mutation in the long loop of LH impaired binding to its
receptor. Long-term hCG treatment resulted in testicular en-
largement, virilization, and an increase in sperm count, but
fertility was not achieved. The normal development of male
external genitalia in this patient likely reflects the in utero
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action of hCG on the LH receptor to generate androgens
during the critical period of genital development.
The clinical phenotype in this patient contrasts with that
seen in patients with inactivating mutations in the LH re-
ceptor, who are unable to respond to either LH or hCG to
produce sufficient testosterone [and dihydrotestosterone
(DHT)] for virilization of the male external genitalia (29).
Phenotypes associated with LH receptor mutations range
from complete failure of virilization to hypospadias, micro-
penis, or absent puberty and infertility, reflecting variable
residual receptor function. An absence of mature Leydig cells
and an arrest of spermatogenesis at the spermatid stage has
been reported, and this diagnosis should be considered in
patients who are diagnosed with Leydig cell hypoplasia and
infertility.
Women with homozygous LH receptor mutations have
been identified within these families (30). These patients
have oligomenorrhea or amenorrhea despite normal puber-
tal development, highlighting the importance of the LH re-
ceptor in ovulation. No homozygous LH gene mutations
have been described in females, although heterozygous LH
gene changes have been described in two women with in-
fertility, and homozygous changes (W8R, I15T) with an extra
glycosylation consensus site (Asn(13)-Ala-Thr) have been
described as population polymorphisms. LH and the LH
receptor therefore remain candidate genes for abnormalities
in a subset of women with infertility.
Testis determination, differentiation, function,
and spermatogenesis
The development of a 46XY fetus into a fertile, phenotypic
male is a dynamic process that requires: development of the
bipotential gonad into a testis (testis determination); differ-
entiation of the Leydig and Sertoli cells within the testis;
androgen biosynthesis by the Leydig cells to virilize the
external genitalia and support development of Wolffian
structures (e.g. prostate); anti-Mullerian hormone [AMH
(Mu¨llerian-inhibiting substance)] production by Sertoli cells
to regress Mu¨llerian structures (e.g. uterus and upper vagi-
na); testicular descent; and migration of germ cells into the
developing gonad leading to spermatogenesis at the time of
puberty. Single gene mutations affecting each of these pro-
cesses have been described in patients with disorders of
sexual development or infertility (Fig. 2 and Table 2) (for
reviews, see Refs. 31 and 32).
Testis determination and differentiation. The testis determining
gene, Sry, was first identified and characterized just over a
decade ago (31). Since then, mutations and deletions in sev-
eral genes involved in the pathways of testis determination/
differentiation have been described in patients with testic-
ular dysgenesis and complete or partial 46XY sex reversal
[e.g. Wilms’ tumor 1, steroidogenic factor-1 (SF1), SRY, SRY-
related HMG-box gene (SOX9), -thalassemia/mental retar-
dation syndrome, X-linked, desert hedgehog]. Associated
features are often present (e.g. adrenal failure (SF1); renal
dysfunction and tumors (WT1) (Denys-Drash syndrome or
Frasier syndrome), campomelic dysplasia (SOX9); see Table
2). Gonadal dysgenesis (46XY karyotype) has also been de-
scribed in patients with chromosomal rearrangements in-
volving deletion of candidate genes for testis development
(e.g. Doublesex- and MAB3-related transcription factor 1/2,
SOX8) or duplication of loci containing antitestis genes (e.g.
Dosage sensitive sex reversal-AHC critical region on the X
chromosome, gene 1 (DAX1), Wingless-type MMTV integra-
tion site family, member 4) (33, 34). Taken together, these
reports highlight the exquisite sensitivity of human gonadal
development to gene dosage effects.
Sex hormone biosynthesis and action. DHT is the most potent
androgen implicated in virilization of the developing male
fetus, and impaired masculinization has been reported in
individuals with a range of steroid biosynthetic defects (e.g.
mutations in steroidogenic acute regulatory protein, P450
side-chain cleavage, 3-hydroxysteroid dehydrogenase type
2; 17-hydroxylase/17,20-lyase, 3-hydroxysteroid dehy-
drogenase type 3). Patients who are unable to convert tes-
tosterone to DHT due to mutations in the gene encoding 5
reductase (SRD5A2) usually show undervirilization at birth
but may develop limited phallic growth in adolescence due
to expression of an alternate isoform of the enzyme at this
time.
Mutations in the AR have been described in more than 200
patients with complete or partial forms of the androgen
insensitivity syndrome (for the Androgen Receptor Data-
base, see http://www.mcgill.ca/androgendb/). These mu-
tations affect the actions of both T and DHT. Milder loss of
function mutations have been reported in patients with im-
FIG. 2. Overview of the development and function of the gonad. Mu-
tations in the genes listed in italics have been reported in humans.
Overexpression of the antitestis genes, DAX1 and WNT4, affect testis
development in 46XY individuals, whereas overexpression or inap-
propriate expression of the testis genes, SRY and SOX9, affect ovarian
development in individuals with a 46XX karyotype.
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paired spermatogenesis alone (36). Furthermore, abnormal-
ities in AR specific coregulators may result in a similar clin-
ical phenotype in patients with normal AR gene sequence
and function (37).
The importance of estrogen for male fertility has been
demonstrated by the reduced sperm viability seen in a pa-
tient with a mutation in the ER (as well as ER knockout
mice), and potentially disordered testicular development
and spermatogenesis in disorders of aromatase action (for
review, see Ref. 38).
Mu¨llerian regression and testicular descent. Mutations in AMH
and the AMHR2 have been reported in males with preserved
Mu¨llerian structures. Mutations in insulin-like 3/relaxin-like
factor have been described recently in several patients with
impaired testicular descent (39).
Spermatogenesis. Spermatogenesis is a complex process that
requires normal germ cell migration, testicular development,
and Sertoli cell function, as well as appropriate maturation,
motility, and penetration of the sperm. Impaired spermato-
genesis and infertility is a feature of many transgenic ani-
mals. Thus, a host of candidate genes exist for impaired
spermatogenesis in humans. Microdeletions of the Y chro-
mosome (including RNA-binding motif protein and Deleted
in azoospermia) have been found in a significant proportion
of men with azoospermia (for review, see Ref. 40), and spe-
cific point mutations in the Ubiquitin-specific protease 9, Y
TABLE 2. Single gene disorders causing impaired gonadal development and function in humans
Gene Locus Inheritance Associated features
Testis determination and differentiation (causing 46XY female or ambiguous genitalia)
WT1 11p13 AD DDS: diffuse mesangial sclerosis, Wilms’ tumor, ambiguous
FS: FSGS, early renal failure, gonadoblastoma, XY female
SF1 (NR5A1) 9p33 AD/AR Primary adrenal failure, uterus
SRY Yp11.3 Y
SOX9 17q24.3–25.1 AD Campomelic dysplasia
ATRX Xq13.3 X-linked Mental retardation, -thalassemia
DHH 12q13.1 AR Minifascicular neuropathy
Sex hormone biosynthesis and action (causing 46XY female or ambiguous genitalia)
SF1 (NR5A1) 9p33 AD/AR Primary adrenal failure, uterus
LHR 2p21 AR Leydig cell hypoplasia
STAR 8p11.2 AR Primary adrenal failure
CYP11A1 15q23–24 AD Primary adrenal failure
HSD3B2 1p13.1 AR Primary adrenal failure
CYP17 10q24–25 AR Postnatal virilization, hypertension
HSD17B3 9q22 AR Partial virilization at puberty
SRD5A2 2p23 AR Partial virilization at puberty
AR Xq11–12 X-linked
Mu¨llerian regression and testicular descent
SF1 (NR5A1) 9p33 AD/AR Primary adrenal failure, 46XY female
AMH 19p13.3–13.2 AR Uterine structures
AMHR2 12q13 AR Uterine structures
INSL3 19p13.2 AD Undescended testes
Spermatogenesis
FSHR 2p21-p16 AR Variable impaired spermatogenesis
GNAS 20q13.1 AD(imprinted) Pseudohypoparathyroidism, hormone resistance
DAX1 Xp21 X-linked Primary adrenal failure, HH
ER 6q25 AR Tall stature, delayed epiphyseal fusion
CYP19 15q21 AR Maternal virilization during pregnancy
AR Xq11–12 X-linked/CAG -
AIRE 21q22.3 AR Autoimmune polyendocrinopathy syndrome type I
DAZ Yq11 Y
RBMY Yq11 Y
USP9Y Yq11.2 Y
DNAH5 5p15-p14 AR Primary ciliary dyskinesia, left-right asymmetry
POLG 15q25 CAG -
Ovarian development and function (not including steroid biosynthetic defects)
FSHR 2p21-p16 AR Variable pubertal development
LHR 2p21 AR Normal puberty, amenorrhea
GNAS 20q13.1 AD(imprinted) Pseudohypoparathyroidism, hormone resistance
AIRE 21q22.3 AR Autoimmune polyendocrinopathy syndrome type I
FMR1 Xq27.3 CAG
Inhibin- 2q33–36 AR
FOXL2 3q23 AD Bletharophimosis-ptosis-epicanthus inversus
AD, Autosomal dominant; AR, autosomal recessive; CAG, differences in trinucleotide repeat sequences; DDS, Denys-Drash syndrome; FS,
Frasier syndrome; FSGS, focal and segmental glomerulosclerosis; DHH, desert hedgehog; LHR, LH receptor; STAR, steroidogenic acute
regulatory protein; CYP11A1, P450 side-chain cleavage; HSD3B2, 3-hydroxysteroid dehydrogenase type 2; CYP17, 17-hydroxylase/17,20-
lyase; HSD17B3, 3-hydroxysteroid dehydrogenase type 3; SRD5A2, 5-reductase; AR, androgen receptor INSL3, insulin-like 3/relaxin-like
factor; FSHR, FSH receptor; CYP19, aromatase.
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chromosome have been described (41). In addition, muta-
tions in dynein, axonemal, heavy chain 5 and dynein, axon-
emal, intermediate chain 1 have been reported recently in
patients with infertility associated with primary ciliary dys-
kinesia and left-right asymmetry (42), and differences in the
length of a trinucleotide repeat within the mitochondrial
gene POLG may be linked to spermatogenic function in the
population.
Ovarian development and function
Although specific ovarian determining genes are yet to be
identified, overexpression (or inappropriate expression) of
testis-specific genes (e.g. SRY, SOX9) in 46XX individuals can
result in the development of testicular tissue and virilization.
Disorders of steroid biosynthesis that affect ovarian estrogen
production will interfere with pubertal development and
ovulation. However, in some situations (e.g. mutations in
STAR) sufficient estrogen can be synthesized to allow partial
pubertal development (43). No ER (/) mutations have
been reported in females, although these would be expected
to impair reproductive function.
Premature ovarian failure (POF) is occasionally familial,
suggesting a genetic basis in some cases. POF loci have been
identified at Xq13.3-q21.1 (POF2) and Xq26.2-q28 (POF1),
possibly involving breakpoint deletions in fragile site mental
retardation 2 or DIAPH2. Premature ovarian failure may also
be associated with trinucleotide repeat differences (premu-
tations) in fragile site mental retardation 1 (FRAXA) and
mutations/polymorphisms in the inhibin- subunit (44), as
well as due to point mutations in the forkhead transcription
factor foxl2 in the blepharophimosis-ptosis-epicanthus in-
versus syndrome (45), the autoimmune regulator 1 gene
in autoimmune polyendocrinopathy syndrome type I, and
guanine nucleotide-binding protein -stimulating activity
polypeptide 1 in pseudohypoparathyroidism (for a review
of primary hypogonadism in females, see http://www.
uptodate.com/html/J Clin Endocrinol Metab./december/
topics/48781). It is likely that many more mutations in genes
involved in oogenesis, follicular maturation, and cell survival/
apoptosis will be identified in women with infertility.
Nuclear receptors expressed throughout the reproductive
axis: SF1 and DAX1
SF1 (NR5A1) and DAX1 (NR0B1) are two orphan nuclear
receptors that are expressed in the hypothalamus, gonado-
tropes, gonads, and adrenals, and regulate the development
and function of the HPG axis at multiple levels. Studies in
mice as well as humans have confirmed the crucial role that
these transcription factors play in reproductive function and
fertility.
SF1. SF1 regulates the transcription of an array of genes
involved in male sexual differentiation, Mu¨llerian regres-
sion, testicular descent, steroidogenesis, and reproduction
(47). Homozygous deletion of Sf1 (/) in mice results in
complete gonadal and adrenal agenesis, phenotypic XY sex-
reversal with persistence of Mu¨llerian structures in males,
abnormalities in the development of the VMH and gonado-
tropes, and obesity. Heterozygous animals have a milder
adrenal phenotype. Furthermore, mice with gonadotrope-
specific deletion of Sf1 have impaired gonadotropin release
and hypogonadism but respond to gonadotropin treatment,
confirming the role of Sf1 in pituitary function.
SF1 mutations have been reported in two patients with
complete XY sex-reversal, testicular dysgenesis, Mu¨llerian
structures, and primary adrenal failure. In the first patient,
a de novo heterozygous G35E mutation was identified in the
P-box of the first zinc finger of SF1 (48). This motif is known
to be a crucial determinant of DNA binding specificity, and
the mutation affects SF1 binding and transactivation of many
target genes (49). Recently, a homozygous R92Q mutation
was identified in the A-box of SF1, a region known to sta-
bilize binding by nuclear receptors that function as mono-
mers (50). Heterozygous carriers have normal fertility. These
cases confirm that SF1 plays a major role in the development
and function of the HPG axis in humans and reveal the
importance of functional gene dosage when one factor reg-
ulates many genes in the reproductive axis (49, 50). However,
the precise role of SF1 in human puberty is less clear as the
first patient had a gonadectomy, and the second patient did
not survive beyond infancy.
A heterozygous mutation in SF1 has also been described
in a girl with primary adrenal failure (51). The presence of
ovaries in this patient suggests that SF1 is not necessary for
ovarian differentiation. Whether this mutation in SF1 will
impair estrogen biosynthesis, thereby preventing the devel-
opment of puberty, remains to be seen.
DAX1. Mutations or deletions in this atypical orphan nuclear
receptor cause X-linked adrenal hypoplasia congenita
(AHC). DAX1 mutations have now been described in almost
100 families with AHC (52). Affected boys usually present
with primary adrenal failure in infancy or early childhood.
Although the HPG axis is often intact in infancy, HH be-
comes apparent at the expected time of puberty. Several
studies have shown that the HH associated with this con-
dition represents defects at the level of the pituitary go-
nadotropes as well as the hypothalamus, consistent with the
expression of DAX1 in both of these structures (53). Conse-
quently, pulsatile GnRH therapy is often ineffective. In ad-
dition, studies of the adrenal hypoplasia congenita and hy-
pogonadism (Dax1) knockout mouse have revealed a crucial
role for Dax1 in testis development and spermatogenesis.
Limited data from patients with X-linked AHC suggest that
DAX1 is involved in spermatogenesis in humans too, and
the response to gonadotropin therapy is usually ineffective
(54, 55).
Most patients with X-linked AHC have nonsense or frame-
shift mutations that truncate the carboxyterminus of DAX1
and severely impair its function as a transcriptional repres-
sor. Missense mutations in DAX1 are less common, and
cluster within the putative ligand-like binding domain (56).
Several patients with variant phenotypes associated with
DAX1 mutations have been reported. For example, extreme
delayed puberty has been described in the female carriers of
DAX1 mutations in one family (54), and HH in the absence
of adrenal dysfunction has been reported in a woman who
is homozygous for a truncation mutation in DAX1 through
gene conversion (57). Although analysis of DAX1 in more
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than 100 patients with idiopathic HH failed to detect any
mutations (58), two patients have now been reported who
presented with partial HH (4–5 ml testes) and delayed-onset
adrenal failure in adulthood (55, 59). The missense mutations
found in these patients (Y380D, I439S) show partial loss of
function in transient gene expression assays, consistent with
the mild clinical phenotype. These reports again highlight
the importance of gene dosage effects in the reproductive
axis (60) and indicate that patients with variant phenotypes
may present after childhood.
Summary
The genetic mutations described in patients with repro-
ductive disorders have provided important insight into the
transcription factors, receptors, and hormones that regulate
the HPG axis in humans. These mutations can affect devel-
opment and function of the HPG axis at many levels. Lab-
oratory investigations and associated features can help to
focus on a gene of interest in some cases, but it is likely that
these reports represent the most severely affected individ-
uals; less severe loss of function mutations may be manifest
as milder clinical phenotypes (e.g. DAX1, LH receptor). Thus,
the true prevalence of these genetic abnormalities in patients
with reproductive dysfunction or infertility is not known.
A major challenge in this field is that mutations lead to
infertility, thereby limiting the investigator’s ability to use
traditional genetic linkage and association studies to identify
candidate genes. However, the human genome project is
starting to have a major impact on strategies used to identify
genetic mutations. The density of polymorphic markers,
such as single nucleotide polymorphisms, is increasing rap-
idly, allowing better gene mapping. In addition, easy access
to the structure of genes known to be involved in reproduc-
tive disorders is allowing high-throughput screening of can-
didate genes. A large number of genes involved in repro-
duction are being identified in transgenic and gene knockout
mice. As these phenotypes are characterized more thor-
oughly, it may be possible to better predict candidate genes
in humans based on characteristic hormonal and histologic
features of particular mutations. Gene microarrays have the
potential to provide gene expression fingerprints associated
with specific types of genetic disorders.
Finally, it is important to translate advances in genetics
into improved clinical management. In addition to genetic
counseling, it may be possible to direct selected patients to
various forms of assisted reproduction such as intracyto-
plasmic sperm injection for spermatogenic defects or in vitro
fertilization for ovulatory dysfunction. The paradigm of us-
ing reproductive physiology and pathophysiology to de-
velop new treatments has a track record of success. In a
relatively short period of time, our understanding of the
physiologic role of gonadotropins has been used to create
recombinant gonadotropins, which are now commonly used
to facilitate reproduction. By analogy, the discovery of ad-
ditional key regulators of gonadal development and game-
togenesis may provide additional therapeutic tools for en-
hancing reproductive function.
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